Progressive Supranuclear Palsy in 2022: recent developments and an eye to the future

Abstract

Progressive supranuclear palsy (PSP) is an uncommon, progressive, neurodegenerative condition which classically presents with eye movement abnormalities, axial rigidity, early falls and cognitive impairment. The range of recognised phenotypes associated with PSP has expanded significantly in recent years. Imaging markers can assist in the diagnosis of PSP, while novel imaging modalities and laboratory-based biomarkers offer hope for earlier and more accurate diagnosis. While no disease modifying treatments are yet available several therapies may be useful in ameliorating symptoms. Despite disappointing recent clinical trial results, several agents are currently under investigation for the treatment of PSP.